1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
CellSource Co., Ltd.

CellSource Co., Ltd.

TTSE:4880
316.00
JPY
-1.00
(-0.32%)
7.28BMarket Cap
Dec 10Next Earn
CellSource Co., Ltd.
TSE:4880
(Tokyo Stock Exchange)

Recent

price

316.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
JPY
30.04
93.57
123.56
102.8
157.78
229.01
238.85
219.93
187.31
- -
Revenue per Share
6.45
14.92
15.3
15.19
35.17
54.54
48.88
12.02
0.54
- -
Basic EPS, GAAP
5.91
14.59
10.88
16.48
45.18
40.1
25.83
2.63
14.28
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
19.88
4.99
- -
Dividend per Share
12.03
23.22
93.04
110.77
146.05
202.59
313.86
304.82
303.58
301.94
Book Value per Share
12.03
22.96
92.79
110.48
145.45
202.03
312.86
301.87
300.74
295.26
Tangible Book Value per Share
17
13
13
18
19
19
19
20
20
20
Basic Weighted Avg Shares
519
1,213
1,612
1,855
2,922
4,274
4,511
4,355
3,711
- -
Sales/Revenue/Turnover
30.66
24.33
20.29
22.4
33.96
36.76
27.08
2.97
4.49
- -
Operating Margin (%)
11
13
21
26
31
45
64
142
198
- -
Depreciation Expense
111
193
200
274
651
1,018
923
238
11
- -
Net Income, GAAP
29.87
34.34
34.2
33.61
35.27
35.73
25.53
19.33
90.3
- -
Effective Tax Rate (%)
21.46
15.95
12.39
14.77
22.29
23.82
20.47
5.46
0.29
- -
Profit Margin (%)
167
246
1,424
1,857
2,312
3,263
5,137
4,627
5,045
4,982
Working Capital
- -
- -
4
1
- -
- -
77
57
36
25
LT Debt
208
401
1,608
2,043
2,720
3,786
6,202
6,037
6,017
5,993
Total Equity
- -
48.05
19.42
14.17
24.08
27.16
17.05
1.66
0.26
- -
Return on Invested Capital (%)
- -
63.5
19.8
14.98
27.33
31.28
18.31
3.85
0.18
- -
Return on Capital (%)
- -
63.5
19.87
15.02
27.35
31.29
18.49
3.89
0.18
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jan'24
Apr'24
Apr'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
25
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
20
20
Market Capitalization
24,737
30,877
7,284

Working Capital

JPY

•

in mil. unless spec.
Jan'24
Apr'24
Apr'26
Total Current Assets
5,388
5,364
5,482
Cash, Cash Equivalents & STI
4,679
4,599
4,787
Accounts Receivable, Net
324
384
304
Inventories
252
232
308
Total Current Liabilities
626
563
500
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
26.64%
-0.34%
Free Cash Flow
- -
98.07%
443.82%
Net Income, GAAP
- -
2.98%
-95.52%
Sales/Revenue/Turnover
- -
18.21%
-14.78%
Total Cash Common Dividend
- -
- -
-74.88%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,174
1,054
- -
- -
4,355
2025
- -
- -
- -
- -
3,711
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7.27
7.88
- -
- -
12.02
2025
- -
- -
- -
- -
0.54
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
19.88
2025
- -
- -
- -
- -
4.99
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
CellSource Co., Ltd. CellSource Co., Ltd. engages primarily in regenerative medicine-related businesses and consumer products in Japan. The company provides processing services for adipose-derived stem cells (ASC) extracted from patients' adipose tissues; processing services for platelet-rich plasma from frozen-defrosted blood (PFC-FD); regulatory compliance support for medical facilities offering regenerative medicine therapies; and manufacturing of specific processed cells, along with sales of related medical equipment. It also develops and markets the Signalift series of anti-aging cosmetics, including serums containing proprietary Signa-Peptide complexes derived from regenerative medicine research. Founded on November 30, 2015, and headquartered at 11F, Shibuya Cast, 1-23-21 Shibuya, Shibuya-ku, Tokyo, Japan, the company operates additional facilities including the Haneda Global Cell Processing Center in Kawasaki-shi, Kanagawa, and holds multiple licenses such as Manufacturing License for Specific Processed Cells (FA3240004), Manufacturing Registration for Medical Devices (13BZ201780), and Marketing License for Cosmetics (13COX11314). CellSource lists on the Tokyo Stock Exchange Prime Market (ticker: 4880). In recent developments, Takashi Sawada assumes the role of Representative Director and CEO as of January 2024, succeeding the founder; the company strengthens its chief officer system effective November 1, 2024, to consolidate decision-making and accelerate execution; and it advances strategic business streamlining, cost discipline, and new growth initiatives amid rapid expansion in orthopedic regenerative medicine applications for musculoskeletal pain relief.